Albemarle Reports Third-Quarter Sales Growth of 11% and Increases Guidance

 
 

ALBemarle Corporation (NYSE: ALB) today announced its results for the third quarter ended September 30, 2021 .

 
 

  Albemarle Corp. Logo. (PRNewsFoto/Albemarle Corporation) 

 
 

  Third-Quarter 2021 Highlights
  (Unless otherwise stated, all percent changes are based on year-over-year comparisons)  

 
  • Net sales of $830.6 million , an increase of 11%; Net sales increased 19% excluding FCS
  •  
  • Net loss of ($392.8) million , or ($3.36) per diluted share
  •  
  • Adjusted diluted EPS of $1.05 , a decrease of 4%, excludes a $4.29 per share charge for a recent arbitration decision
  •  
  • Adjusted EBITDA of $217.6 million , an increase of 1%; Adjusted EBITDA increased 14% excluding FCS
  •  
  • Increased FY 2021 guidance based on strong third-quarter performance
  •  
  • Announced agreement to acquire Guangxi Tianyuan New Energy Materials (Tianyuan), which includes a lithium conversion plant (Qinzhou) designed to produce 25,000 mtpa with the potential to expand to 50,000 mtpa
  •  
  • Announced agreements for strategic investments in China with plans to build two lithium hydroxide conversion plants, each initially targeting 50,000 mtpa
  •  
  • MARBL Lithium Joint Venture (MARBL) to restart operations at the Wodgina Lithium Mine in Australia  
  •  
  • Advanced deployment of Albemarle Way of Excellence (AWE) operating model and submitted sustainability disclosure report to CDP (formerly the Carbon Disclosure Project)
  •  

"Despite supply chain challenges and increased raw material costs last quarter, we continued to deliver solid revenue and adjusted EBITDA growth," said Albemarle CEO Kent Masters . "In October, we achieved first lithium carbonate production at our new La Negra III/IV conversion facility. We are making investments to add significant conversion capacity in China , initially targeting up to 150,000 metric tons of lithium hydroxide per year which will provide high-return growth opportunities aligned with the increasing demand from our customers."

 

  Outlook  

 

  Albemarle's improved outlook for full-year 2021 reflects a strong third-quarter performance and assumes continued global economic recovery as well as a modest improvement in operating performance compared to full-year 2020. Full-year 2021 net sales guidance was revised higher which reflects higher volumes in its Lithium business and stronger pricing in its Bromine businesses. Adjusted EBITDA guidance improved due to higher net sales, as well as lower corporate costs and higher-than-expected Catalysts joint venture income. Capital expenditures were revised higher due to accelerated investments in growth, tight labor markets, and COVID-related travel restrictions in Western Australia .

 
 
                     
 
 
 

   FY 2021 Guidance (1)   

 
 

  Net sales  

 
 
 

  $3.3 - $3.4 billion  

 
 

  Adjusted EBITDA  

 
 
 

  $830 - $860 million  

 
 

  Adjusted EBITDA Margin  

 
 
 

  ~25%  

 
 

  Adjusted Diluted EPS  

 
 
 

  $3.85 - $4.15  

 
 

  Net Cash from Operations  

 
 
 

  $550 - $650 million  

 
 

  Capital Expenditures  

 
 
 

  $925 - $975 million  

 
 
 
 
   
 
 

  (1)  

 
 

  Guidance reflects the sale of Albemarle's Fine Chemistry Services (FCS) business to W.R. Grace which closed on June 1, 2021.  

 
 
 

  COVID-19 Response  

 

  Albemarle's cross-functional Global Response Team continues to meet regularly to address employee health and safety and operational challenges. The company's priority is always the health and well-being of its employees, customers, and communities. The company continues to focus on building in the flexibility needed to adjust for regional differences and changing conditions.

 

  Third-Quarter Results  

 
 
                                                                                                       
 

   In millions, except per share amounts   

 
 

   Q3 2021   

 
 
 

   Q3 2020   

 
 
 

   $ Change   

 
 
 

   % Change   

 
 

  Net sales  

 
 

  $  

 
 

  830.6  

 
 
 
 

  $  

 
 

  746.9  

 
 
 
 

  $  

 
 

  83.7  

 
 
 
 

  11.2  

 
 

  %  

 
 

  Net (loss) income attributable to Albemarle
Corporation
 

 
 

  $  

 
 

  (392.8)  

 
 
 
 

  $  

 
 

  98.3  

 
 
 
 

  $  

 
 

  (491.1)  

 
 
 
 

  (499.6)  

 
 

  %  

 
 

  Adjusted EBITDA (a)  

 
 

  $  

 
 

  217.6  

 
 
 
 

  $  

 
 

  216.1  

 
 
 
 

  $  

 
 

  1.5  

 
 
 
 

  0.7  

 
 

  %  

 
 

  Diluted earnings per share  

 
 

  $  

 
 

  (3.36)  

 
 
 
 

  $  

 
 

  0.92  

 
 
 
 

  $  

 
 

  (4.28)  

 
 
 
 

  (465.2)  

 
 

  %  

 
 

  Non-operating pension and OPEB items (a)  

 
 

  (0.04)  

 
 
 
 

  (0.02)  

 
 
 
 
 
 
 

  Non-recurring and other unusual items (a)  

 
 

  4.42  

 
 
 
 

  0.19  

 
 
 
 
 
 
 

  Adjusted diluted earnings per share (a)(b)  

 
 

  $  

 
 

  1.05  

 
 
 
 

  $  

 
 

  1.09  

 
 
 
 

  $  

 
 

  (0.04)  

 
 
 
 

  (3.7)  

 
 

  %  

 
 
 
 
     
 
 

  (a)  

 
 

  See Non-GAAP Reconciliations for further details.  

 
 

  (b)  

 
 

  Totals may not add due to rounding.  

 
 
 

Net sales of $830.6 million increased by $83.7 million compared to the prior-year quarter, primarily driven by an increase in sales from the company's Lithium and Bromine businesses, partially offset by the loss of revenue from its Fine Chemistry Services (FCS) business which was sold on June 1, 2021 .

 

Adjusted EBITDA of $217.6 million increased by $1.5 million from the prior-year quarter primarily due to higher  Lithium results, offset by the sale of FCS and an expense of $13.5 million for the correction of out-of-period errors regarding misstated inventory foreign exchange values relating to prior periods.

 

Net loss attributable to Albemarle of ($392.8) million includes a $657 .4 million ( $504.5 million after income taxes) charge related to a recent arbitration decision on a dispute regarding Huntsman Corporation's acquisition of Rockwood's Pigments & Additives business in 2014. The Huntsman-Rockwood dispute is a legacy dispute that Albemarle inherited when it purchased all outstanding equity of Rockwood Holdings, Inc. in 2015, acquiring its lithium and other business lines unrelated to the dispute. The company continues to assess its legal rights and options. Albemarle and Huntsman have initiated discussions regarding a resolution of the matter.

 

The effective income tax rate for the third quarter of 2021 was 22.2% compared to 25.2% in the same period of 2020. The difference is largely due to a $152.9 million tax benefit recorded in Q3 2021 related to an accrual recorded for a legal arbitration ruling. On an adjusted basis, the effective income tax rates were 19.2% and 16.7% for the third quarter of 2021 and 2020, respectively.

 

  Business Segment Results  

 

  Lithium  

 
 
                                      
 

   In millions   

 
 

   Q3 2021   

 
 
 

   Q3 2020   

 
 
 

   $ Change   

 
 
 

   % Change   

 
 

  Net Sales  

 
 

  $  

 
 

  359.2  

 
 
 
 

  $  

 
 

  265.6  

 
 
 
 

  $  

 
 

  93.6  

 
 
 
 

  35.2  

 
 

  %  

 
 

  Adjusted EBITDA  

 
 

  $  

 
 

  125.4  

 
 
 
 

  $  

 
 

  97.8  

 
 
 
 

  $  

 
 

  27.6  

 
 
 
 

  28.3  

 
 

  %  

 
 
 

Lithium net sales of $359.2 million increased $93.6 million (+35%) primarily due to higher volume (+30%) from tolling to help meet growing customer demand and higher pricing and FX (+5%). Adjusted EBITDA of $125.4 million increased $27.6 million primarily due to increased net sales and higher volume at its Talison joint venture.

 

   Current Trends:   Full-year 2021 adjusted EBITDA is expected to grow in the mid- to high-teens year over year, up from previous guidance. Volume growth for full-year 2021 is expected to grow in the mid-teens driven primarily by tolling. Average realized pricing is expected to increase sequentially due to tightening market conditions and full-year pricing will be flat to slightly higher compared to 2020. Full-year 2021 average margin is expected to remain below 35% due to higher costs related to project start-ups and tolling, partially offset by productivity improvements.

 

  Albemarle remains on track to complete construction of Kemerton I by the end of the year with sales expected to begin in the second half of 2022. Due to the ongoing labor shortages and pandemic-related travel restrictions in Western Australia , Kemerton II is now expected to complete construction in the second half of 2022.

 

During the quarter, the company made significant progress on its Wave 3 lithium expansion projects. Albemarle entered an agreement to acquire Tianyuan, which owns a lithium conversion plant, Qinzhou, designed to produce up to 25,000 metric tons per annum and with the potential to expand to 50,000 metric tons per annum. Additionally, it entered agreements for strategic investments in China and will move forward with design, engineering, and permitting plans to build two new lithium hydroxide conversion plants, each initially targeting 50,000 metric tons per annum.

 

Our MARBL joint venture recently announced plans to restart one of the Wodgina mine's three processing lines, each of which has installed processing capacity of 250,000 metric tons per annum of spodumene concentrate. Production is expected to begin in the third quarter of 2022.

 

  Bromine Specialties  

 
 
                                      
 

   In millions   

 
 

   Q3 2021   

 
 
 

   Q3 2020   

 
 
 

   $ Change   

 
 
 

   % Change   

 
 

  Net Sales  

 
 

  $  

 
 

  277.8  

 
 
 
 

  $  

 
 

  237.2  

 
 
 
 

  $  

 
 

  40.6  

 
 
 
 

  17.1  

 
 

  %  

 
 

  Adjusted EBITDA  

 
 

  $  

 
 

  86.0  

 
 
 
 

  $  

 
 

  79.4  

 
 
 
 

  $  

 
 

  6.6  

 
 
 
 

  8.3  

 
 

  %  

 
 
 

Bromine net sales of $277.8 million increased $40.6 million (+17%) owing to strong pricing and FX (+17%) while volume remained flat (0%). Pricing was driven by high demand across the product portfolio and tight market conditions. Adjusted EBITDA of $86.0 million increased $6.6 million due to higher net sales, partially offset by higher costs for raw materials and freight. While sales increased during the quarter, the lack of inventory and a force majeure declaration by the company's chlorine supplier limited the company's ability to capitalize on strong demand strength and increased brine production capacity.

 

   Current Trends:   The company expects full-year 2021 adjusted EBITDA growth in the low-double digits, up from previous guidance due to strength in demand for flame retardants, as well as benefiting from diverse end markets. Volumes will remain constrained during the remainder of the year due to sold-out conditions and the lack of inventory. Bromine's ongoing cost savings initiatives and higher pricing are expected to partially offset higher freight and raw material costs.

 

  Catalysts  

 
 
                                      
 

   In millions   

 
 

   Q3 2021   

 
 
 

   Q3 2020   

 
 
 

   $ Change   

 
 
 

   % Change   

 
 

  Net Sales  

 
 

  $  

 
 

  193.6  

 
 
 
 

  $  

 
 

  197.9  

 
 
 
 

  $  

 
 

  (4.4)  

 
 
 
 

  (2.2)  

 
 

  %  

 
 

  Adjusted EBITDA  

 
 

  $  

 
 

  33.1  

 
 
 
 

  $  

 
 

  37.8  

 
 
 
 

  $  

 
 

  (4.7)  

 
 
 
 

  (12.5)  

 
 

  %  

 
 
 

Catalysts net sales of $193.6 million decreased $4.4 million (-2%) compared to the previous year, primarily due to slightly lower volume (-1%) and pricing and FX (-1%). Adjusted EBITDA of $33.1 million declined $4.7 million mostly due to lower sales and cost pressures, partially offset by higher-than-expected equity income.

 

   Current Trends:   The company revised its expectations for full-year 2021 adjusted EBITDA to decline between 20% and 25%, an improvement from previous guidance, owing to higher-than-expected joint venture income. The year-over-year decline in adjusted EBITDA is primarily due to the impact of the U.S. Gulf Coast winter storm, product mix, and the previously disclosed change in a customer's order patterns during the first quarter. While market conditions continue to improve, volumes are not expected to return to pre-pandemic levels before late 2022 or 2023.

 

  All Other  

 
 
                                      
 

   In millions   

 
 

   Q3 2021   

 
 
 

   Q3 2020   

 
 
 

   $ Change   

 
 
 

   % Change   

 
 

  Net Sales  

 
 

  $  

 
 

  

 
 
 
 

  $  

 
 

  46.1  

 
 
 
 

  $  

 
 

  (46.1)  

 
 
 
 

  (100.0)  

 
 

  %  

 
 

  Adjusted EBITDA  

 
 

  $  

 
 

  

 
 
 
 

  $  

 
 

  25.0  

 
 
 
 

  $  

 
 

  (25.0)  

 
 
 
 

  (100.0)  

 
 

  %  

 
 
 

Other operations represent the FCS business which was sold on June 1, 2021 .

 

  Balance Sheet and Liquidity  

 

As of September 30, 2021 , Albemarle had estimated liquidity of approximately $2.0 billion , including $595.0 million of cash and equivalents, the full $1.0 billion available under the company's revolver, $270.0 million remaining under its delayed draw term loan and $131.5 million on other available credit lines. Total debt was $2.0 billion , representing net debt to adjusted EBITDA of approximately 1.7 times.

 

  Cash Flow and Capital Deployment  

 

Cash from operations for the nine months ended September 30, 2021 , of $490.6 million increased $28.9 million versus the prior year driven by working capital inflows and higher revenues in the company's Lithium and Bromine segments. Capital expenditures of $652.7 million increased by $31.4 million versus the prior year as the company nears completion of its Wave 2 Lithium expansion projects.

 

  Albemarle's primary capital allocation priorities are to grow profitably, fund its dividend, and maintain its financial flexibility and its Investment Grade credit rating.

 

In October, the board declared a quarterly dividend of $0.39 per share, an increase over the quarterly dividend paid in 2020. This is Albemarle's 27th consecutive year of a dividend increase. The company's share repurchase authorization remains in place; however, the company has no near-term plans to execute share buybacks.

 

  Earnings Call  

 
 
          
 

  Date:  

 
 

  Thursday, November 4, 2021  

 
 

  Time:  

 
 

  9:00 AM Eastern time  

 
 

  Dial-in (U.S.):  

 
 

  844-347-1034  

 
 

  Dial-in (International):  

 
 

  209-905-5910  

 
 

  Passcode:  

 
 

  6875708  

 
 
 

The company's earnings presentation and supporting material are available on Albemarle's website at https://investors.albemarle.com .

 

  About Albemarle   

 

 ALBemarle Corporation (NYSE: ALB) is a global specialty chemicals company with leading positions in lithium, bromine and refining catalysts. We think beyond business as usual to power the potential of companies in many of the world's largest and most critical industries, such as energy, electronics, and transportation. We actively pursue a sustainable approach to managing our diverse global footprint of world-class resources. In conjunction with our highly experienced and talented global teams, our deep-seated values, and our collaborative customer relationships, we create value-added and performance-based solutions that enable a safer and more sustainable future.

 

We regularly post information to www.albemarle.com , including notification of events, news, financial performance, investor presentations and webcasts, non-GAAP reconciliations, SEC filings and other information regarding our company, its businesses and the markets it serves.

 

  Forward-Looking Statements  

 

Some of the information presented in this press release, the conference call and discussions that follow, including, without limitation, information related to the timing of active and proposed projects, product development, production capacity, committed volumes, market trends, pricing, financial flexibility, expected growth, anticipated return on opportunities, earnings and demand for our products, input costs, productivity improvements, surcharges, tax rates, stock repurchases, dividends, cash flow generation, costs and cost synergies, capital projects, future acquisition and divestiture transactions, expected benefits from proposed transactions, economic trends, outlook and all other information relating to matters that are not historical facts may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from the views expressed. Factors that could cause actual results to differ materially from the outlook expressed or implied in any forward-looking statement include, without limitation: changes in economic and business conditions; changes in financial and operating performance of our major customers and industries and markets served by us; the timing of orders received from customers; the gain or loss of significant customers; competition from other manufacturers; changes in the demand for our products or the end-user markets in which our products are sold; limitations or prohibitions on the manufacture and sale of our products; availability of raw materials; increases in the cost of raw materials and energy, and our ability to pass through such increases to our customers; changes in our markets in general; fluctuations in foreign currencies; changes in laws and government regulation impacting our operations or our products; the occurrence of regulatory actions, proceedings, claims or litigation; the occurrence of cyber-security breaches, terrorist attacks, industrial accidents, natural disasters or climate change; hazards associated with chemicals manufacturing; the inability to maintain current levels of product or premises liability insurance or the denial of such coverage; political unrest affecting the global economy, including adverse effects from terrorism or hostilities; political instability affecting our manufacturing operations or joint ventures; changes in accounting standards; the inability to achieve results from our global manufacturing cost reduction initiatives as well as our ongoing continuous improvement and rationalization programs; changes in the jurisdictional mix of our earnings and changes in tax laws and rates; changes in monetary policies, inflation or interest rates that may impact our ability to raise capital or increase our cost of funds, impact the performance of our pension fund investments and increase our pension expense and funding obligations; volatility and uncertainties in the debt and equity markets; technology or intellectual property infringement, including cyber-security breaches, and other innovation risks; decisions we may make in the future; the ability to successfully execute, operate and integrate acquisitions and divestitures; uncertainties as to the duration and impact of the coronavirus (COVID-19) pandemic; and the other factors detailed from time to time in the reports we file with the SEC, including those described under "Risk Factors" in our most recent Annual Report on Form 10-K any subsequently filed Quarterly Reports on Form 10-Q. These forward-looking statements speak only as of the date of this press release. We assume no obligation to provide any revisions to any forward-looking statements should circumstances change, except as otherwise required by securities and other applicable laws.

 
 
                                                                                                                                                                                                                                                                                            
 

  Albemarle Corporation and Subsidiaries  

 
 

  Consolidated Statements of Income  

 
 

  (In Thousands Except Per Share Amounts) (Unaudited)  

 
 
 
 

   Three Months Ended   

 
 
 

   Nine Months Ended   

 
 
 

   September 30,   

 
 
 

   September 30,   

 
 
 

   2021   

 
 
 

   2020   

 
 
 

   2021   

 
 
 

   2020   

 
 

   Net sales   

 
 

  $  

 
 

  830,566  

 
 
 
 

  $  

 
 

  746,868  

 
 
 
 

  $  

 
 

  2,433,753  

 
 
 
 

  $  

 
 

  2,249,762  

 
 
 

  Cost of goods sold  

 
 

  581,293  

 
 
 
 

  492,812  

 
 
 
 

  1,672,376  

 
 
 
 

  1,520,329  

 
 
 

   Gross profit   

 
 

  249,273  

 
 
 
 

  254,056  

 
 
 
 

  761,377  

 
 
 
 

  729,433  

 
 
 

  Selling, general and administrative expenses  

 
 

  103,477  

 
 
 
 

  96,092  

 
 
 
 

  318,180  

 
 
 
 

  304,918  

 
 
 

  Research and development expenses  

 
 

  13,289  

 
 
 
 

  13,532  

 
 
 
 

  41,901  

 
 
 
 

  43,839  

 
 
 

  Gain on sale of business  

 
 

  984  

 
 
 
 

  

 
 
 
 

  (428,424)  

 
 
 
 

  

 
 
 

   Operating profit   

 
 

  131,523  

 
 
 
 

  144,432  

 
 
 
 

  829,720  

 
 
 
 

  380,676  

 
 
 

  Interest and financing expenses  

 
 

  (5,136)  

 
 
 
 

  (19,227)  

 
 
 
 

  (56,170)  

 
 
 
 

  (53,964)  

 
 
 

  Other expense, net  

 
 

  (643,196)  

 
 
 
 

  (3,661)  

 
 
 
 

  (631,870)  

 
 
 
 

  (1,620)  

 
 
 

  (Loss) income before income taxes and equity in net
income of unconsolidated investments
 

 
 

  (516,809)  

 
 
 
 

  121,544  

 
 
 
 

  141,680  

 
 
 
 

  325,092  

 
 
 

  Income tax (benefit) expense  

 
 

  (114,670)  

 
 
 
 

  30,653  

 
 
 
 

  14,422  

 
 
 
 

  64,526  

 
 
 

  (Loss) income before equity in net income of
unconsolidated investments
 

 
 

  (402,139)  

 
 
 
 

  90,891  

 
 
 
 

  127,258  

 
 
 
 

  260,566  

 
 
 

  Equity in net income of unconsolidated investments (net of
tax)
 

 
 

  27,706  

 
 
 
 

  26,154  

 
 
 
 

  62,215  

 
 
 
 

  83,872  

 
 
 

  Net (loss) income  

 
 

  (374,433)  

 
 
 
 

  117,045  

 
 
 
 

  189,473  

 
 
 
 

  344,438  

 
 
 

  Net income attributable to noncontrolling interests  

 
 

  (18,348)  

 
 
 
 

  (18,744)  

 
 
 
 

  (61,977)  

 
 
 
 

  (53,309)  

 
 
 

  Net (loss) income attributable to Albemarle Corporation  

 
 

  $  

 
 

  (392,781)  

 
 
 
 

  $  

 
 

  98,301  

 
 
 
 

  $  

 
 

  127,496  

 
 
 
 

  $  

 
 

  291,129  

 
 
 

  Basic (loss) earnings per share  

 
 

  $  

 
 

  (3.36)  

 
 
 
 

  $  

 
 

  0.92  

 
 
 
 

  $  

 
 

  1.10  

 
 
 
 

  $  

 
 

  2.74  

 
 
 

  Diluted (loss) earnings per share  

 
 

  $  

 
 

  (3.36)  

 
 
 
 

  $  

 
 

  0.92  

 
 
 
 

  $  

 
 

  1.10  

 
 
 
 

  $  

 
 

  2.73  

 
 
 
 
 
 
 
 
 
 
 

  Weighted-average common shares outstanding – basic  

 
 

  116,965  

 
 
 
 

  106,386  

 
 
 
 

  115,455  

 
 
 
 

  106,314  

 
 
 

  Weighted-average common shares outstanding – diluted  

 
 

  116,965  

 
 
 
 

  106,873  

 
 
 
 

  116,140  

 
 
 
 

  106,640  

 
 
 
 

 

 
 
                                                                                                                                                                                                                                                      
 

  Albemarle Corporation and Subsidiaries  

 
 

  Condensed Consolidated Balance Sheets  

 
 

  (In Thousands) (Unaudited)  

 
 
 
 

   September 30,   

 
 
 

   December 31,   

 
 
 

   2021   

 
 
 

   2020   

 
 

   ASSETS   

 
 
 
 
 

  Current assets:  

 
 
 
 
 

  Cash and cash equivalents  

 
 

  $  

 
 

  595,049  

 
 
 
 

  $  

 
 

  746,724  

 
 
 

  Trade accounts receivable  

 
 

  520,746  

 
 
 
 

  530,838  

 
 
 

  Other accounts receivable  

 
 

  56,298  

 
 
 
 

  61,958  

 
 
 

  Inventories  

 
 

  745,598  

 
 
 
 

  750,237  

 
 
 

  Other current assets  

 
 

  160,415  

 
 
 
 

  116,427  

 
 
 

  Total current assets  

 
 

  2,078,106  

 
 
 
 

  2,206,184  

 
 
 

  Property, plant and equipment  

 
 

  7,783,962  

 
 
 
 

  7,427,641  

 
 
 

  Less accumulated depreciation and amortization  

 
 

  2,128,485  

 
 
 
 

  2,073,016  

 
 
 

  Net property, plant and equipment  

 
 

  5,655,477  

 
 
 
 

  5,354,625  

 
 
 

  Investments  

 
 

  902,504  

 
 
 
 

  656,244  

 
 
 

  Other assets  

 
 

  251,786  

 
 
 
 

  219,268  

 
 
 

  Goodwill  

 
 

  1,623,471  

 
 
 
 

  1,665,520  

 
 
 

  Other intangibles, net of amortization  

 
 

  320,981  

 
 
 
 

  349,105  

 
 
 

  Total assets  

 
 

  $  

 
 

  10,832,325  

 
 
 
 

  $  

 
 

  10,450,946  

 
 
 

   LIABILITIES AND EQUITY   

 
 
 
 
 

  Current liabilities:  

 
 
 
 
 

  Accounts payable  

 
 

  $  

 
 

  545,922  

 
 
 
 

  $  

 
 

  483,221  

 
 
 

  Accrued expenses  

 
 

  956,506  

 
 
 
 

  440,763  

 
 
 

  Current portion of long-term debt  

 
 

  611  

 
 
 
 

  804,677  

 
 
 

  Dividends payable  

 
 

  45,450  

 
 
 
 

  40,937  

 
 
 

  Income taxes payable  

 
 

  42,553  

 
 
 
 

  32,251  

 
 
 

  Total current liabilities  

 
 

  1,591,042  

 
 
 
 

  1,801,849  

 
 
 

  Long-term debt  

 
 

  2,021,487  

 
 
 
 

  2,767,381  

 
 
 

  Postretirement benefits  

 
 

  47,020  

 
 
 
 

  48,075  

 
 
 

  Pension benefits  

 
 

  299,875  

 
 
 
 

  340,818  

 
 
 

  Other noncurrent liabilities  

 
 

  617,488  

 
 
 
 

  629,377  

 
 
 

  Deferred income taxes  

 
 

  360,181  

 
 
 
 

  394,852  

 
 
 

  Commitments and contingencies  

 
 
 
 
 

  Equity:  

 
 
 
 
 

  Albemarle Corporation shareholders' equity:  

 
 
 
 
 

  Common stock  

 
 

  1,170  

 
 
 
 

  1,069  

 
 
 

  Additional paid-in capital  

 
 

  2,913,383  

 
 
 
 

  1,438,038  

 
 
 

  Accumulated other comprehensive loss  

 
 

  (366,436)  

 
 
 
 

  (326,132)  

 
 
 

  Retained earnings  

 
 

  3,145,999  

 
 
 
 

  3,155,252  

 
 
 

  Total Albemarle Corporation shareholders' equity  

 
 

  5,694,116  

 
 
 
 

  4,268,227  

 
 
 

  Noncontrolling interests  

 
 

  201,116  

 
 
 
 

  200,367  

 
 
 

  Total equity  

 
 

  5,895,232  

 
 
 
 

  4,468,594  

 
 
 

  Total liabilities and equity  

 
 

  $  

 
 

  10,832,325  

 
 
 
 

  $  

 
 

  10,450,946  

 
 
 
 

 

 
 
                                                                                                                                                                                                                                                      
 

  Albemarle Corporation and Subsidiaries  

 
 

  Selected Consolidated Cash Flow Data  

 
 

  (In Thousands) (Unaudited)  

 
 
 
 

   Nine Months Ended   

 

   September 30,   

 
 
 

   2021   

 
 
 

   2020   

 
 

  Cash and cash equivalents at beginning of year  

 
 

  $  

 
 

  746,724  

 
 
 
 

  $  

 
 

  613,110  

 
 
 

  Cash flows from operating activities:  

 
 
 
 
 

  Net income  

 
 

  189,473  

 
 
 
 

  344,438  

 
 
 

  Adjustments to reconcile net income to cash flows from operating activities:  

 
 
 
 
 

  Depreciation and amortization  

 
 

  185,765  

 
 
 
 

  170,214  

 
 
 

  Gain on sale of business  

 
 

  (428,424)  

 
 
 
 

  

 
 
 

  Stock-based compensation and other  

 
 

  14,668  

 
 
 
 

  15,864  

 
 
 

  Equity in net income of unconsolidated investments (net of tax)  

 
 

  (62,215)  

 
 
 
 

  (83,872)  

 
 
 

  Dividends received from unconsolidated investments and nonmarketable
securities
 

 
 

  43,374  

 
 
 
 

  61,309  

 
 
 

  Pension and postretirement benefit  

 
 

  (12,451)  

 
 
 
 

  (4,975)  

 
 
 

  Pension and postretirement contributions  

 
 

  (24,145)  

 
 
 
 

  (10,323)  

 
 
 

  Unrealized gain on investments in marketable securities  

 
 

  (3,912)  

 
 
 
 

  (3,377)  

 
 
 

  Loss on early extinguishment of debt  

 
 

  28,955  

 
 
 
 

  

 
 
 

  Deferred income taxes  

 
 

  (38,924)  

 
 
 
 

  7,920  

 
 
 

  Working capital changes  

 
 

  456,405  

 
 
 
 

  (167,436)  

 
 
 

  Non-cash transfer of 40% value of construction in progress of Kemerton plant
to MRL
 

 
 

  135,928  

 
 
 
 

  131,929  

 
 
 

  Other, net  

 
 

  6,089  

 
 
 
 

  23  

 
 
 

  Net cash provided by operating activities  

 
 

  490,586  

 
 
 
 

  461,714  

 
 
 

  Cash flows from investing activities:  

 
 
 
 
 

  Acquisitions, net of cash acquired  

 
 

  

 
 
 
 

  (22,572)  

 
 
 

  Capital expenditures  

 
 

  (652,739)  

 
 
 
 

  (621,371)  

 
 
 

  Cash proceeds from divestitures, net  

 
 

  289,791  

 
 
 
 

  

 
 
 

  Sales of marketable securities, net  

 
 

  4,407  

 
 
 
 

  1,208  

 
 
 

  Investments in equity and other corporate investments  

 
 

  (286)  

 
 
 
 

  (786)  

 
 
 

  Net cash used in investing activities  

 
 

  (358,827)  

 
 
 
 

  (643,521)  

 
 
 

  Cash flows from financing activities:  

 
 
 
 
 

  Proceeds from issuance of common stock  

 
 

  1,453,888  

 
 
 
 

  

 
 
 

  Repayments of long-term debt and credit agreements  

 
 

  (1,173,823)  

 
 
 
 

  (250,000)  

 
 
 

  Proceeds from borrowings of credit agreements  

 
 

  

 
 
 
 

  452,163  

 
 
 

  Other debt repayments, net  

 
 

  (327,292)  

 
 
 
 

  202,786  

 
 
 

  Fees related to early extinguishment of debt  

 
 

  (24,877)  

 
 
 
 

  

 
 
 

  Dividends paid to shareholders  

 
 

  (132,236)  

 
 
 
 

  (120,836)  

 
 
 

  Dividends paid to noncontrolling interests  

 
 

  (61,178)  

 
 
 
 

  (14,286)  

 
 
 

  Proceeds from exercise of stock options  

 
 

  16,220  

 
 
 
 

  16,925  

 
 
 

  Withholding taxes paid on stock-based compensation award distributions  

 
 

  (7,755)  

 
 
 
 

  (4,803)  

 
 
 

  Other  

 
 

  (1,384)  

 
 
 
 

  (2,751)  

 
 
 

  Net cash (used in) provided by financing activities  

 
 

  (258,437)  

 
 
 
 

  279,198  

 
 
 

  Net effect of foreign exchange on cash and cash equivalents  

 
 

  (24,997)  

 
 
 
 

  (8,428)  

 
 
 

  Increase in cash and cash equivalents  

 
 

  (151,675)  

 
 
 
 

  88,963  

 
 
 

  Cash and cash equivalents at end of period  

 
 

  $  

 
 

  595,049  

 
 
 
 

  $  

 
 

  702,073  

 
 
 
 

 

 
 
                                                                                                                                                                                                
 

  Albemarle Corporation and Subsidiaries  

 
 

  Consolidated Summary of Segment Results  

 
 

  (In Thousands) (Unaudited)  

 
 
 
 

   Three Months Ended   

 
 
 

   Nine Months Ended   

 
 
 

   September 30,   

 
 
 

   September 30,   

 
 
 

   2021   

 
 
 

   2020   

 
 
 

   2021   

 
 
 

   2020   

 
 

   Net sales:   

 
 
 
 
 
 
 
 
 

  Lithium  

 
 

  $  

 
 

  359,229  

 
 
 
 

  $  

 
 

  265,646  

 
 
 
 

  $  

 
 

  958,539  

 
 
 
 

  $  

 
 

  786,186  

 
 
 

  Bromine Specialties  

 
 

  277,783  

 
 
 
 

  237,193  

 
 
 
 

  837,978  

 
 
 
 

  701,564  

 
 
 

  Catalysts  

 
 

  193,554  

 
 
 
 

  197,919  

 
 
 
 

  562,141  

 
 
 
 

  602,179  

 
 
 

  All Other  

 
 

  

 
 
 
 

  46,110  

 
 
 
 

  75,095  

 
 
 
 

  159,833  

 
 
 

  Total net sales  

 
 

  $  

 
 

  830,566  

 
 
 
 

  $  

 
 

  746,868  

 
 
 
 

  $  

 
 

  2,433,753  

 
 
 
 

  $  

 
 

  2,249,762  

 
 
 
 
 
 
 
 
 
 
 

   Adjusted EBITDA:   

 
 
 
 
 
 
 
 
 

  Lithium  

 
 

  $  

 
 

  125,416  

 
 
 
 

  $  

 
 

  97,789  

 
 
 
 

  $  

 
 

  341,293  

 
 
 
 

  $  

 
 

  270,962  

 
 
 

  Bromine Specialties  

 
 

  86,012  

 
 
 
 

  79,448  

 
 
 
 

  273,298  

 
 
 
 

  235,751  

 
 
 

  Catalysts  

 
 

  33,103  

 
 
 
 

  37,834  

 
 
 
 

  79,694  

 
 
 
 

  108,081  

 
 
 

  All Other  

 
 

  

 
 
 
 

  24,985  

 
 
 
 

  29,858  

 
 
 
 

  66,407  

 
 
 

  Corporate  

 
 

  (26,962)  

 
 
 
 

  (24,001)  

 
 
 
 

  (81,892)  

 
 
 
 

  (83,588)  

 
 
 

  Total adjusted EBITDA  

 
 

  $  

 
 

  217,569  

 
 
 
 

  $  

 
 

  216,055  

 
 
 
 

  $  

 
 

  642,251  

 
 
 
 

  $  

 
 

  597,613  

 
 
 
 

See accompanying non-GAAP reconciliations below.

 

  Additional Information  

 

It should be noted that adjusted net income attributable to Albemarle Corporation, adjusted diluted earnings per share, non-operating pension and OPEB items per diluted share, non-recurring and other unusual items per diluted share, adjusted effective income tax rates, EBITDA, adjusted EBITDA, EBITDA margin and adjusted EBITDA margin are financial measures that are not required by, or presented in accordance with, accounting principles generally accepted in the United States , or GAAP. These non-GAAP measures should not be considered as alternatives to Net income attributable to Albemarle Corporation ("earnings") or other comparable measures calculated and reported in accordance with GAAP. These measures are presented here to provide additional useful measurements to review the company's operations, provide transparency to investors and enable period-to-period comparability of financial performance. The company's chief operating decision maker uses these measures to assess the ongoing performance of the company and its segments, as well as for business and enterprise planning purposes.

 

A description of other non-GAAP financial measures that Albemarle uses to evaluate its operations and financial performance, and reconciliation of these non-GAAP financial measures to the most directly comparable financial measures calculated and reported in accordance with GAAP can be found on the following pages of this press release, which is also is available on Albemarle's website at https://investors.albemarle.com . The company does not provide a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable financial measures calculated and reported in accordance with GAAP, as the company is unable to estimate significant non-recurring or unusual items without unreasonable effort. The amounts and timing of these items are uncertain and could be material to the company's results calculated in accordance with GAAP.

 

   ALBEMARLE CORPORATION AND SUBSIDIARIES
  Non-GAAP Reconciliations
  (Unaudited)  

 

See below for a reconciliation of adjusted net income attributable to Albemarle Corporation, EBITDA and adjusted EBITDA, the non-GAAP financial measures, to Net income attributable to Albemarle Corporation ("earnings"), the most directly comparable financial measure calculated and reported in accordance with GAAP. Adjusted earnings is defined as earnings before the non-recurring, other unusual and non-operating pension and other post-employment benefit (OPEB) items as listed below. The non-recurring and unusual items may include acquisition and integration related costs, gains or losses on sales of businesses, restructuring charges, facility divestiture charges, certain litigation and arbitration costs and charges, and other significant non-recurring items. EBITDA is defined as earnings before interest and financing expenses, income tax expense, and depreciation and amortization. Adjusted EBITDA is defined as EBITDA plus or minus the non-recurring, other unusual and non-operating pension and OPEB items as listed below.

 
 
                                                                                                                                                                                                                                                                                                    
 
 

   Three Months Ended   

 
 
 

   Nine Months Ended   

 
 
 

   September 30,   

 
 
 

   September 30,   

 
 

   In thousands, except percentages and per share amounts   

 
 

   2021   

 
 
 

   2020   

 
 
 

   2021   

 
 
 

   2020   

 
 

  Net (loss) income attributable to Albemarle Corporation  

 
 

  $  

 
 

  (392,781)  

 
 
 
 

  $  

 
 

  98,301  

 
 
 
 

  $  

 
 

  127,496  

 
 
 
 

  $  

 
 

  291,129  

 
 
 

  Add back:  

 
 
 
 
 
 
 
 
 

  Non-operating pension and OPEB items (net of tax)  

 
 

  (4,271)  

 
 
 
 

  (2,294)  

 
 
 
 

  (12,811)  

 
 
 
 

  (6,904)  

 
 
 

  Non-recurring and other unusual items (net of tax)  

 
 

  520,392  

 
 
 
 

  20,278  

 
 
 
 

  237,157  

 
 
 
 

  29,678  

 
 
 

  Adjusted net income attributable to Albemarle Corporation  

 
 

  $  

 
 

  123,340  

 
 
 
 

  $  

 
 

  116,285  

 
 
 
 

  $  

 
 

  351,842  

 
 
 
 

  $  

 
 

  313,903  

 
 
 
 
 
 
 
 
 
 
 

  Adjusted diluted earnings per share  

 
 

  $  

 
 

  1.05  

 
 
 
 

  $  

 
 

  1.09  

 
 
 
 

  $  

 
 

  3.03  

 
 
 
 

  $  

 
 

  2.94  

 
 
 
 
 
 
 
 
 
 
 

  Weighted-average common shares outstanding – diluted  

 
 

  117,685  

 
 
 
 

  106,873  

 
 
 
 

  116,140  

 
 
 
 

  106,640  

 
 
 
 
 
 
 
 
 
 
 

  Net (loss) income attributable to Albemarle Corporation  

 
 

  $  

 
 

  (392,781)  

 
 
 
 

  $  

 
 

  98,301  

 
 
 
 

  $  

 
 

  127,496  

 
 
 
 

  $  

 
 

  291,129  

 
 
 

  Add back:  

 
 
 
 
 
 
 
 
 

  Interest and financing expenses  

 
 

  5,136  

 
 
 
 

  19,227  

 
 
 
 

  56,170  

 
 
 
 

  53,964  

 
 
 

  Income tax expense  

 
 

  (114,670)  

 
 
 
 

  30,653  

 
 
 
 

  14,422  

 
 
 
 

  64,526  

 
 
 

  Depreciation and amortization  

 
 

  62,082  

 
 
 
 

  58,679  

 
 
 
 

  185,765  

 
 
 
 

  170,214  

 
 
 

   EBITDA   

 
 

  (440,233)  

 
 
 
 

  206,860  

 
 
 
 

  383,853  

 
 
 
 

  579,833  

 
 
 

  Non-operating pension and OPEB items  

 
 

  (5,471)  

 
 
 
 

  (2,901)  

 
 
 
 

  (16,407)  

 
 
 
 

  (8,704)  

 
 
 

  Non-recurring and other unusual items (excluding items
associated with interest expense)
 

 
 

  663,273  

 
 
 
 

  12,096  

 
 
 
 

  274,805  

 
 
 
 

  26,484  

 
 
 

   Adjusted EBITDA   

 
 

  $  

 
 

  217,569  

 
 
 
 

  $  

 
 

  216,055  

 
 
 
 

  $  

 
 

  642,251  

 
 
 
 

  $  

 
 

  597,613  

 
 
 
 
 
 
 
 
 
 
 

  Net sales  

 
 

  $  

 
 

  830,566  

 
 
 
 

  $  

 
 

  746,868  

 
 
 
 

  $  

 
 

  2,433,753  

 
 
 
 

  $  

 
 

  2,249,762  

 
 
 

  EBITDA margin  

 
 

  (53.0)  

 
 

  %  

 
 
 

  27.7  

 
 

  %  

 
 
 

  15.8  

 
 

  %  

 
 
 

  25.8  

 
 

  %  

 
 

  Adjusted EBITDA margin  

 
 

  26.2  

 
 

  %  

 
 
 

  28.9  

 
 

  %  

 
 
 

  26.4  

 
 

  %  

 
 
 

  26.6  

 
 

  %  

 
 
 

See below for a reconciliation of adjusted EBITDA on a segment basis, the non-GAAP financial measure, to Net income attributable to Albemarle Corporation, the most directly comparable financial measure calculated and reported in accordance with GAAP (in thousands, except percentages).

 
 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
 
 

   Lithium   

 
 
 

   Bromine
Specialties
 
 

 
 
 

   Catalysts   

 
 
 

   Reportable
Segments
Total
 
 

 
 
 

   All
Other
 
 

 
 
 

   Corporate   

 
 
 

   Consolidated
Total
 
 

 
 
 

   % of
Net
Sales
 
 

 
 

   Three months ended September
30, 2021
 
 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

  Net income (loss) attributable to
Albemarle Corporation
 

 
 

  $  

 
 

  92,449  

 
 
 
 

  $  

 
 

  73,409  

 
 
 
 

  $  

 
 

  20,039  

 
 
 
 

  $  

 
 

  185,897  

 
 
 
 

  $  

 
 

  

 
 
 
 

  $  

 
 

  (578,678)  

 
 
 
 

  $  

 
 

  (392,781)  

 
 
 
 

  (47.3)  

 
 

  %  

 
 

  Depreciation and amortization  

 
 

  34,256  

 
 
 
 

  12,603  

 
 
 
 

  13,064  

 
 
 
 

  59,923  

 
 
 
 

  

 
 
 
 

  2,159  

 
 
 
 

  62,082  

 
 
 
 

  7.5  

 
 

  %  

 
 

  Non-recurring and other unusual
items
 

 
 

  (1,289)  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  (1,289)  

 
 
 
 

  

 
 
 
 

  664,562  

 
 
 
 

  663,273  

 
 
 
 

  79.9  

 
 

  %  

 
 

  Interest and financing expenses  

 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  5,136  

 
 
 
 

  5,136  

 
 
 
 

  0.6  

 
 

  %  

 
 

  Income tax expense  

 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  (114,670)  

 
 
 
 

  (114,670)  

 
 
 
 

  (13.8)  

 
 

  %  

 
 

  Non-operating pension and
OPEB items
 

 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  (5,471)  

 
 
 
 

  (5,471)  

 
 
 
 

  (0.7)  

 
 

  %  

 
 

   Adjusted EBITDA   

 
 

  $  

 
 

  125,416  

 
 
 
 

  $  

 
 

  86,012  

 
 
 
 

  $  

 
 

  33,103  

 
 
 
 

  $  

 
 

  244,531  

 
 
 
 

  $  

 
 

  

 
 
 
 

  $  

 
 

  (26,962)  

 
 
 
 

  $  

 
 

  217,569  

 
 
 
 

  26.2  

 
 

  %  

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

   Three months ended September
30, 2020
 
 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

  Net income (loss) attributable to
Albemarle Corporation
 

 
 

  $  

 
 

  69,102  

 
 
 
 

  $  

 
 

  66,548  

 
 
 
 

  $  

 
 

  25,176  

 
 
 
 

  $  

 
 

  160,826  

 
 
 
 

  $  

 
 

  22,798  

 
 
 
 

  $  

 
 

  (85,323)  

 
 
 
 

  $  

 
 

  98,301  

 
 
 
 

  13.2  

 
 

  %  

 
 

  Depreciation and amortization  

 
 

  28,687  

 
 
 
 

  12,900  

 
 
 
 

  12,658  

 
 
 
 

  54,245  

 
 
 
 

  2,187  

 
 
 
 

  2,247  

 
 
 
 

  58,679  

 
 
 
 

  7.9  

 
 

  %  

 
 

  Non-recurring and other unusual
items
 

 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  12,096  

 
 
 
 

  12,096  

 
 
 
 

  1.6  

 
 

  %  

 
 

  Interest and financing expenses  

 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  19,227  

 
 
 
 

  19,227  

 
 
 
 

  2.6  

 
 

  %  

 
 

  Income tax expense  

 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  30,653  

 
 
 
 

  30,653  

 
 
 
 

  4.1  

 
 

  %  

 
 

  Non-operating pension and
OPEB items
 

 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  (2,901)  

 
 
 
 

  (2,901)  

 
 
 
 

  (0.4)  

 
 

  %  

 
 

   Adjusted EBITDA   

 
 

  $  

 
 

  97,789  

 
 
 
 

  $  

 
 

  79,448  

 
 
 
 

  $  

 
 

  37,834  

 
 
 
 

  $  

 
 

  215,071  

 
 
 
 

  $  

 
 

  24,985  

 
 
 
 

  $  

 
 

  (24,001)  

 
 
 
 

  $  

 
 

  216,055  

 
 
 
 

  28.9  

 
 

  %  

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

   Nine months ended September
30, 2021
 
 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

  Net income (loss) attributable to
Albemarle Corporation
 

 
 

  $  

 
 

  237,293  

 
 
 
 

  $  

 
 

  235,670  

 
 
 
 

  $  

 
 

  41,401  

 
 
 
 

  $  

 
 

  514,364  

 
 
 
 

  $  

 
 

  27,988  

 
 
 
 

  $  

 
 

  (414,856)  

 
 
 
 

  $  

 
 

  127,496  

 
 
 
 

  5.2  

 
 

  %  

 
 

  Depreciation and amortization  

 
 

  99,559  

 
 
 
 

  37,628  

 
 
 
 

  38,293  

 
 
 
 

  175,480  

 
 
 
 

  1,870  

 
 
 
 

  8,415  

 
 
 
 

  185,765  

 
 
 
 

  7.6  

 
 

  %  

 
 

  Non-recurring and other unusual
items (excluding items
associated with interest expense)
 

 
 

  4,441  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  4,441  

 
 
 
 

  

 
 
 
 

  270,364  

 
 
 
 

  274,805  

 
 
 
 

  11.3  

 
 

  %  

 
 

  Interest and financing expenses  

 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  56,170  

 
 
 
 

  56,170  

 
 
 
 

  2.3  

 
 

  %  

 
 

  Income tax expense  

 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  14,422  

 
 
 
 

  14,422  

 
 
 
 

  0.6  

 
 

  %  

 
 

  Non-operating pension and
OPEB items
 

 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  (16,407)  

 
 
 
 

  (16,407)  

 
 
 
 

  (0.7)  

 
 

  %  

 
 

   Adjusted EBITDA   

 
 

  $  

 
 

  341,293  

 
 
 
 

  $  

 
 

  273,298  

 
 
 
 

  $  

 
 

  79,694  

 
 
 
 

  $  

 
 

  694,285  

 
 
 
 

  $  

 
 

  29,858  

 
 
 
 

  $  

 
 

  (81,892)  

 
 
 
 

  $  

 
 

  642,251  

 
 
 
 

  26.4  

 
 

  %  

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

   Nine months ended September
30, 2020
 
 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

  Net income (loss) attributable to
Albemarle Corporation
 

 
 

  $  

 
 

  188,380  

 
 
 
 

  $  

 
 

  198,905  

 
 
 
 

  $  

 
 

  70,770  

 
 
 
 

  $  

 
 

  458,055  

 
 
 
 

  $  

 
 

  60,069  

 
 
 
 

  $  

 
 

  (226,995)  

 
 
 
 

  $  

 
 

  291,129  

 
 
 
 

  12.9  

 
 

  %  

 
 

  Depreciation and amortization  

 
 

  82,582  

 
 
 
 

  36,846  

 
 
 
 

  37,311  

 
 
 
 

  156,739  

 
 
 
 

  6,338  

 
 
 
 

  7,137  

 
 
 
 

  170,214  

 
 
 
 

  7.6  

 
 

  %  

 
 

  Non-recurring and other unusual
items
 

 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  26,484  

 
 
 
 

  26,484  

 
 
 
 

  1.2  

 
 

  %  

 
 

  Interest and financing expenses  

 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  53,964  

 
 
 
 

  53,964  

 
 
 
 

  2.4  

 
 

  %  

 
 

  Income tax expense  

 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  64,526  

 
 
 
 

  64,526  

 
 
 
 

  2.9  

 
 

  %  

 
 

  Non-operating pension and
OPEB items
 

 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  (8,704)  

 
 
 
 

  (8,704)  

 
 
 
 

  (0.4)  

 
 

  %  

 
 

   Adjusted EBITDA   

 
 

  $  

 
 

  270,962  

 
 
 
 

  $  

 
 

  235,751  

 
 
 
 

  $  

 
 

  108,081  

 
 
 
 

  $  

 
 

  614,794  

 
 
 
 

  $  

 
 

  66,407  

 
 
 
 

  $  

 
 

  (83,588)  

 
 
 
 

  $  

 
 

  597,613  

 
 
 
 

  26.6  

 
 

  %  

 
 
 

Non-operating pension and OPEB items, consisting of mark-to-market actuarial gains/losses, settlements/curtailments, interest cost and expected return on assets, are not allocated to Albemarle's operating segments and are included in the Corporate category. In addition, the company believes that these components of pension cost are mainly driven by market performance, and the company manages these separately from the operational performance of the company's businesses. In accordance with GAAP, these non-operating pension and OPEB items are included in Other income (expenses), net. Non-operating pension and OPEB items were as follows (in thousands):

 
 
                                                            
 
 

   Three Months Ended   

 
 
 

   Nine Months Ended   

 
 
 

   September 30,   

 
 
 

   September 30,   

 
 
 

   2021   

 
 
 

   2020   

 
 
 

   2021   

 
 
 

   2020   

 
 

  Interest cost  

 
 

  $  

 
 

  5,422  

 
 
 
 

  $  

 
 

  7,164  

 
 
 
 

  $  

 
 

  16,280  

 
 
 
 

  $  

 
 

  21,452  

 
 
 

  Expected return on assets  

 
 

  (10,893)  

 
 
 
 

  (10,065)  

 
 
 
 

  (32,687)  

 
 
 
 

  (30,156)  

 
 
 

  Total  

 
 

  $  

 
 

  (5,471)  

 
 
 
 

  $  

 
 

  (2,901)  

 
 
 
 

  $  

 
 

  (16,407)  

 
 
 
 

  $  

 
 

  (8,704)  

 
 
 
 

In addition to the non-operating pension and OPEB items disclosed above, the company has identified certain other items and excluded them from Albemarle's adjusted net income calculation for the periods presented. A listing of these items, as well as a detailed description of each follows below (per diluted share):

 
 
                                                                                                                                    
 
 

   Three Months Ended   

 
 
 

   Nine Months Ended   

 
 
 

   September 30,   

 
 
 

   September 30,   

 
 
 

   2021   

 
 
 

   2020   

 
 
 

   2021   

 
 
 

   2020   

 
 

  Restructuring and other (1)  

 
 

  $  

 
 

  

 
 
 
 

  $  

 
 

  0.02  

 
 
 
 

  $  

 
 

  0.01  

 
 
 
 

  $  

 
 

  0.08  

 
 
 

  Acquisition and integration related costs (2)  

 
 

  0.01  

 
 
 
 

  0.04  

 
 
 
 

  0.04  

 
 
 
 

  0.10  

 
 
 

  Albemarle Foundation contribution (3)  

 
 

  

 
 
 
 

  

 
 
 
 

  0.13  

 
 
 
 

  

 
 
 

  Gain on sale of business (4)  

 
 

  0.01  

 
 
 
 

  

 
 
 
 

  (2.85)  

 
 
 
 

  

 
 
 

  Loss on early extinguishment of debt (5)  

 
 

  

 
 
 
 

  

 
 
 
 

  0.21  

 
 
 
 

  

 
 
 

  Legal accrual (6)  

 
 

  4.29  

 
 
 
 

  

 
 
 
 

  4.34  

 
 
 
 

  

 
 
 

  Other (7)  

 
 

  0.02  

 
 
 
 

  0.02  

 
 
 
 

  0.11  

 
 
 
 

  0.01  

 
 
 

  Discrete tax items (8)  

 
 

  0.09  

 
 
 
 

  0.11  

 
 
 
 

  0.05  

 
 
 
 

  0.09  

 
 
 

  Total non-recurring and other unusual items  

 
 

  $  

 
 

  4.42  

 
 
 
 

  $  

 
 

  0.19  

 
 
 
 

  $  

 
 

  2.04  

 
 
 
 

  $  

 
 

  0.28  

 
 
 
 
 
                                                                                 
 
 

  (1)  

 
 

  During the three and nine months ended September 30, 2021, Albemarle recorded facility closure costs related to offices in Germany, and severance expenses in Germany and Belgium, in Selling, general and administrative expenses of $0.8 million and $2.3 million ($0.5 million and $1.6 million after income taxes, or less than $0.01 and $0.01 per share), respectively. In 2020, Albemarle recorded severance expenses as part of business reorganization plans, impacting each of its businesses and Corporate, primarily in the U.S., Germany and with its Jordanian joint venture partner. During the three months ended September 30, 2020, the company recorded expenses of $2.3 million ($1.7 million after income taxes, or $0.02 per share) in Selling, general and administrative expenses. During the nine months ended September 30, 2020, the company recorded severance expenses in Cost of goods sold, Selling, general and administrative expenses and Net income attributable to noncontrolling interest of $0.7 million, $10.4 million and a $0.3 million gain ($7.9 million after income taxes, or $0.08 per share), respectively. The balance of unpaid severance is recorded in Accrued expenses and is expected to primarily be paid through 2021.  

 
 
 
 

  (2)  

 
 

  Costs related to the acquisition, integration and divestitures of various significant projects, recorded in Selling, general and administrative expenses for the three and nine months ended September 30, 2021 were $1.6 million and $5.6 million ($1.2 million and $4.5 million after income taxes, or $0.01 and $0.04 per share), respectively, and for the three and nine months ended September 30, 2020 were $5.9 million and $14.3 million ($4.6 million and $11.1 million after income taxes, or $0.04 and $0.10 per share), respectively.  

 
 
 
 

  (3)  

 
 

  Included in Selling, general and administrative expenses for the nine months ended September 30, 2021 is a charitable contribution of $20.0 million ($15.5 million after income taxes, or $0.13 per share), using a portion of the proceeds received from the FCS divestiture, to the Albemarle Foundation, a non-profit organization that sponsors grants, health and social projects, educational initiatives, disaster relief, matching gift programs, scholarships and other charitable initiatives in locations where Albemarle's employees live and the company operates. This contribution is in addition to the normal annual contribution made to the Albemarle Foundation by the company, and is significant in size and nature in that it is intended to provide more long-term benefits in these communities.  

 
 
 
 

  (4)  

 
 

  Included in Gain on sale of business for the nine months ended September 30, 2021 is $428.4 million ($330.9 million after discrete income taxes, or $2.85 per share) related to the sale of the FCS business. During the three months ended September 30, 2021, the gain on the sale of the FCS business was adjusted down by $1.0 million ($0.8 million after discrete income taxes, or $0.01 per share) for working capital adjustments.  

 
 
 
 

  (5)  

 
 

  Included in Interest and financing expenses for the nine months ended September 30, 2021 is a loss on early extinguishment of debt of $29.0 million ($23.8 million after income taxes, or $0.21 per share), representing the tender premiums, fees, unamortized discounts and unamortized deferred financing costs from the redemption of $1.5 billion in debt using the proceeds from the issuance of common stock.  

 
 
 
 

  (6)  

 
 

  Included in Other expense, net for the three and nine months ended September 30, 2021 is a $657.4 million ($504.5 million after income taxes, or $4.34 per share) charge related to a recent arbitration decision on a dispute regarding Huntsman Corporation's acquisition of Rockwood's Pigments & Additives business in 2014. The Huntsman-Rockwood dispute is a legacy dispute that Albemarle inherited when it purchased all outstanding equity of Rockwood Holdings, Inc. in 2015, acquiring its lithium and other business lines unrelated to the dispute.  

 
 
 
 

  (7)  

 
 

  Other adjustments for the three months ended September 30, 2021 included amounts recorded in:  

 
 
 

  

 
 

  Selling, general and administrative expenses - $2.5 million of expenses primarily related to non-routine labor and compensation related costs that are outside normal compensation arrangements.  

 
 
 

  

 
 

  Other income (expense), net - $0.1 million of a loss resulting from the adjustment of indemnification obligations related to previously disposed businesses.  

 
 
 

  After income taxes, these charges totaled $1.9 million, or $0.02 per share.  

 
 
 
 
 

  Other adjustments for the nine months ended September 30, 2021 included amounts recorded in:  

 
 
 

  

 
 

  Selling, general and administrative expenses - $8.6 million of expenses primarily related to non-routine labor and compensation related costs that are outside normal compensation arrangements, a $4.0 million loss resulting from the sale of property, plant and equipment and $1.6 million of charges for an environmental reserve at a site not part of the company's operations.  

 
 
 

  

 
 

  Other income (expense), net - $3.7 million of expenses primarily related to asset retirement obligation charges to update an estimate at a site formerly owned by Albemarle.  

 
 
 

  After income taxes, these charges totaled $13.3 million, or $0.11 per share.  

 
 
 
 
 

  Other adjustments for the three months ended September 30, 2020 included amounts recorded in:  

 
 
 

  

 
 

  Selling, general and administrative expenses - $3.8 million of a net expense primarily relating to the increase of environmental reserves at sites that we are no longer operating or previously sold.  

 
 
 

  

 
 

  Other income (expense), net - $0.2 million loss resulting from the settlement of a historical legal matter of an acquired company.  

 
 
 

  After income taxes, these charges totaled $2.7 million, or $0.02 per share.  

 
 
 
 
 

  Other adjustments for the nine months ended September 30, 2020 included amounts recorded in:  

 
 
 

  

 
 

  Selling, general and administrative expenses - $3.8 million of a net expense primarily relating to the increase of environmental reserves at sites that we are no longer operating or previously sold.  

 
 
 

  

 
 

  Other income (expense), net - $2.5 million net gain resulting from the settlement of legal matters related to a business and site sold, and $0.8 million net gain primarily relating to the sale of idle properties in Germany, partially offset by a $0.8 million loss resulting from the adjustment of indemnification obligations related to previously disposed businesses.  

 
 
 
 
 

  After income taxes, these net gains totaled $1.0 million, or $0.01 per share.  

 
 
 
 

  (8)  

 
 

  Included in Income tax expense for the three and nine months ended September 30, 2021 are discrete net tax expenses of $11.5 million, or $0.09 per share and net tax expenses of $4.9 million, or $0.05 per share, respectively. The net expense for the three months is primarily related to the impact of discrete tax expense related to global intangible low-taxed income and foreign uncertain tax positions, partially offset by a benefit for excess tax benefits realized from stock-based compensation arrangements. The net expense for the nine months is primarily related to discrete tax expense related to global intangible low-taxed income, tax expense due to an out-of-period adjustment regarding an overstated deferred tax liability for the three-month period ended December 31, 2017 and foreign uncertain tax positions. This is partially offset by the release of a foreign valuation allowance, excess tax benefits realized from stock-based compensation arrangements, and the revaluation of deferred taxes due to tax rate changes.  

 
 
 
 
 

  Included in Income tax expense for the three and nine months ended September 30, 2020 are discrete net tax expenses of $11.3 million, or $0.11 per share, and $9.7 million, or $0.09 per share, respectively. The net expense for the three months was primarily related to expenses for foreign uncertain tax positions and foreign return to accrual adjustments. The net expense for the nine months was primarily related to expenses for foreign uncertain tax positions and foreign return to accrual adjustments, partially offset by a benefit for excess tax benefits realized from stock-based compensation arrangements.  

 
 
 

See below for a reconciliation of the adjusted effective income tax rate, the non-GAAP financial measure, to the effective income tax rate, the most directly comparable financial measure calculated and reported in accordance with GAAP (in thousands, except percentages).

 
 
                                                                                                                                                                        
 
 

   Income before
income taxes and
equity in net income
of unconsolidated
investments
 
 

 
 
 

   Income tax expense   

 
 
 

   Effective income tax
rate
 
 

 
 

   Three months ended September 30, 2021   

 
 
 
 
 
 
 

  As reported  

 
 

  $  

 
 

  (516,809)  

 
 
 
 

  $  

 
 

  (114,670)  

 
 
 
 

  22.2  

 
 

  %  

 
 

  Non-recurring, other unusual and non-operating pension and OPEB
items
 

 
 

  657,802  

 
 
 
 

  141,681  

 
 
 
 
 

  As adjusted  

 
 

  $  

 
 

  140,993  

 
 
 
 

  $  

 
 

  27,011  

 
 
 
 

  19.2  

 
 

  %  

 
 
 
 
 
 
 
 

   Three months ended September 30, 2020   

 
 
 
 
 
 
 

  As reported  

 
 

  $  

 
 

  121,544  

 
 
 
 

  $  

 
 

  30,653  

 
 
 
 

  25.2  

 
 

  %  

 
 

  Non-recurring, other unusual and non-operating pension and OPEB
items
 

 
 

  9,195  

 
 
 
 

  (8,789)  

 
 
 
 
 

  As adjusted  

 
 

  $  

 
 

  130,739  

 
 
 
 

  $  

 
 

  21,864  

 
 
 
 

  16.7  

 
 

  %  

 
 
 
 
 
 
 
 

   Nine months ended September 30, 2021   

 
 
 
 
 
 
 

  As reported  

 
 

  $  

 
 

  141,680  

 
 
 
 

  $  

 
 

  14,422  

 
 
 
 

  10.2  

 
 

  %  

 
 

  Non-recurring, other unusual and non-operating pension and OPEB
items
 

 
 

  287,345  

 
 
 
 

  62,999  

 
 
 
 
 

  As adjusted  

 
 

  $  

 
 

  429,025  

 
 
 
 

  $  

 
 

  77,421  

 
 
 
 

  18.0  

 
 

  %  

 
 
 
 
 
 
 
 

   Nine months ended September 30, 2020   

 
 
 
 
 
 
 

  As reported  

 
 

  $  

 
 

  325,092  

 
 
 
 

  $  

 
 

  64,526  

 
 
 
 

  19.8  

 
 

  %  

 
 

  Non-recurring, other unusual and non-operating pension and OPEB
items
 

 
 

  18,101  

 
 
 
 

  (4,994)  

 
 
 
 
 

  As adjusted  

 
 

  $  

 
 

  343,193  

 
 
 
 

  $  

 
 

  59,532  

 
 
 
 

  17.4  

 
 

  %  

 
 
 

 

 
 
 

 Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/albemarle-reports-third-quarter-sales-growth-of-11-and-increases-guidance-301415725.html  

 

SOURCE Albemarle Corporation

 
 

News Provided by PR Newswire via QuoteMedia

The Conversation (0)
Digital hexagons overlay construction site with an excavator and cloudy sky in the background.

Ekin Ober on Why AI Could Be Mining’s Most Valuable Tool Yet

For Ekin Ober, bringing generative artificial intelligence (AI) to the critical metals sector through her work at Aethos Labs wasn’t just about technological innovation — it reshaped how she thinks about strategy and sustainability in mining.

Now a principal at Kinterra Capital, Ober applies that broad, cross-disciplinary lens to investment decisions, emphasizing the importance of digital fluency, stakeholder alignment and long-term viability.

Her experience helps her identify operational bottlenecks and social license challenges early — essential in guiding assets like nickel and copper projects from concept to production.

Keep reading...Show less
Stacks of US$100 bills with upward-pointing wooden arrows.

Chris Berry: The West Must Invest in Refinement Now or Fall Further Behind

China’s grip on the battery metals sector has drawn increasing scrutiny in recent years as nations confront growing concerns around supply chain risk and resource security.

Through a blend of domestic output and aggressive overseas investment, particularly in Africa and South America, Chinese companies now command a significant share of upstream supply.

The country is responsible for roughly 60 percent of global rare earths production and controls over 70 percent of cobalt supply through its stakes in mines across the Democratic Republic of Congo.

Keep reading...Show less
Magnifying glass focusing on the Albemarle website logo.

Albemarle's Commitment to Sustainability Shines in New Report

As global demand for critical minerals intensifies, Albemarle (NYSE:ALB) continues to position itself as a global leader not only in lithium production but also in sustainable practices.

In its newly released 2024 sustainability report, titled “Values-Led, Purpose-Driven,” the company underscores its commitment to reducing its environmental footprint across six continents, supporting global supply chains and promoting human rights across operations.

From cutting freshwater intensity at its Chilean operations by 28 percent to procuring 24 percent of its electricity from renewable sources, Albemarle is striving to grow its energy storage business while keeping carbon emissions flat, as it translates ESG goals into action.

Keep reading...Show less
Metallic battery with a world map etched on it, against a dark background.

3 Key Themes from Fastmarkets' 2025 Lithium Supply & Battery Raw Materials Event

Market volatility, Chinese control, supply chain risk mitigation and financing emerged as some of the most prevalent themes at the 2025 Fastmarket’s Lithium Supply Battery Raw Materials (LBRM) conference in Las Vegas.

The event, which is in its 17th year, drew a crowd of roughly 1000 delegates, industry experts and analysts, to discuss the current landscape and future projections of the battery materials sector.

During his opening remarks, Fastmarkets CEO Raju Daswani highlighted the growth and maturation the battery raw materials sector has experienced.

Keep reading...Show less
Metals Australia (ASX:MLS)

Metals Australia


Keep reading...Show less

Latest Press Releases

Related News

×